On Wednesday, Guggenheim reaffirmed its Buy rating and $170.00 price target for Praxis Precision Medicines Inc. (NASDAQ:PRAX), following the company's third-quarter update for the fiscal year 2024. The firm highlighted several key points from the update, including the announcement that the interim analysis for Praxis's ulixacaltamide Essential3 Study 1, which is currently enrolling 400 participants, has been rescheduled from the fourth quarter of 2024 to the first quarter of 2025. Despite this shift, management maintains that their guidance for a New Drug Application (NDA) filing in 2025 is still on track.
The interim analysis will provide Praxis with the opportunity to adjust the study's sample size if necessary, potentially increasing the probability of success for the trial. Guggenheim expressed a positive outlook on the stock's potential, estimating that it could significantly move based on the Essential Tremor (ET) data expected from the study.
Additionally, Praxis's management team has expressed confidence in the success of their program and plans to restart their study on Parkinson's disease. The firm also noted Praxis's ongoing enrollment for the Phase II RADIANT study of PRAX-628, now known as vormatrigine, which is being tested on patients with FOS or generalized epilepsy. Topline results for this study are anticipated in the first half of 2025.
Praxis has also initiated the POWER1 study, the first of two Phase II/III trials in FOS, and following promising Phase II EMBOLD results, the company has begun a second cohort of the study. This cohort is aimed at being sufficient for registration, targeting enrollment of 80 patients, with topline results expected by the company in the first half of 2026. Furthermore, a registrational study named EMERALD in all developmental and epileptic encephalopathies (DEEs) is planned for the first half of 2025 after discussions with regulators. Guggenheim's reiteration of the Buy rating and price target reflects their continued confidence in Praxis Precision Medicines Inc.
In other recent news, Praxis Precision Medicines has been making notable strides in its research and development efforts. The pharmaceutical company has updated its executive severance terms, which include enhanced benefits in certain circumstances, reflecting its commitment to retaining top leadership. In the realm of clinical trials, Praxis's drug candidate, Relutrigine, demonstrated a significant 46% reduction in motor seizures in a Phase 2 study, with over 30% of patients achieving freedom from seizures. These results have been positively received by various analyst firms, including Piper Sandler, Truist Securities, TD (TSX:TD) Cowen, Needham, Oppenheimer, and Guggenheim, all of which maintained their positive ratings on the company. Furthermore, Praxis's Phase 3 clinical trial for another drug candidate, Ulixa, is expected to yield key data soon. Praxis is also planning further clinical trials, with interim Essential3 Part1 analysis expected in the fourth quarter of 2024, and the anticipated release of the relutrigine EMBOLD data in the third quarter of 2024. These recent developments underline the company's ongoing progress in its pursuit of innovative treatments.
InvestingPro Insights
To complement Guggenheim's positive outlook on Praxis Precision Medicines Inc. (NASDAQ:PRAX), recent data from InvestingPro offers additional perspective on the company's financial position and market performance.
According to InvestingPro data, Praxis has demonstrated remarkable market performance, with a one-year price total return of 391.85% as of the latest available data. This aligns with the company's ongoing clinical developments and potential market opportunities highlighted in the article. The stock is currently trading near its 52-week high, with its price at 93.65% of the 52-week high value.
InvestingPro Tips reveal that Praxis holds more cash than debt on its balance sheet, which could provide financial flexibility as the company advances its clinical trials and potential NDA filing in 2025. Additionally, six analysts have revised their earnings upwards for the upcoming period, potentially reflecting growing confidence in the company's pipeline and strategic direction.
It's worth noting that while Praxis shows promise in its clinical developments, the company is not currently profitable, with a negative P/E ratio of -10.19 for the last twelve months as of Q2 2024. This is not uncommon for biopharmaceutical companies in the development stage, and investors should consider this alongside the potential of Praxis's drug candidates.
For readers interested in a more comprehensive analysis, InvestingPro offers 13 additional tips for Praxis Precision Medicines, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.